首页|Mechanism of PARP inhibitor resistance and potential overcoming strategies

Mechanism of PARP inhibitor resistance and potential overcoming strategies

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
PARP inhibitors(PARPi)are a kind of cancer therapy that targets poly(ADP-ribose)polymerase.PARPi is the first clinically approved drug to exert synthetic lethality by obstruct-ing the DNA single-strand break repair process.Despite the significant therapeutic effect in pa-tients with homologous recombination(HR)repair deficiency,innate and acquired resistance to PARPi is a main challenge in the clinic.In this review,we mainly discussed the underlying mechanisms of PARPi resistance and summarized the promising solutions to overcome PARPi resistance,aiming at extending PARPi application and improving patient outcomes.

Drug resistanceHomologous recombinationPARPPARP inhibitorPoly(ADP-ribose)polymerase

Xiaoyu Fu、Ping Li、Qi Zhou、Ruyuan He、Guannan Wang、Shiya Zhu、Amir Bagheri、Gary Kupfer、Huadong Pei、Juanjuan Li

展开 >

Department of Oncology,Georgetown Lombardi Comprehensive Cancer Center,Georgetown University Medical Center,Washington,DC 20057,USA

Department of Breast and Thyroid Surgery,Renmin Hospital of Wuhan University,Wuhan,Hubei 430060,China

Cancer Center,Renmin Hospital of Wuhan University,Wuhan,Hubei 430060,China

Department of Thoracic Surgery,Renmin Hospital of Wuhan University,Wuhan,Hubei 430060,China

展开 >

2024

10.1016/j.gendis.2023.02.014

基因与疾病(英文)

基因与疾病(英文)

ISSN：
年,卷(期)：2024.11(1)
  • 139